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Abstract
Colorectal cancer is a common malignancy and a leading cause of cancer related death.
Cancer staging following resection is key to determining any adjuvant therapy in those
patients with high risk disease. In colorectal cancer, tumour stage and lymph node stage
are the main pathological factors which have been considered to influence outcome.
Increasing emphasis is now being placed on other factors, especially the presence of extra-
mural venous invasion (EMVI). It is important to understand the relationship of EMVI with
other pathological factors and to confirm that in an individual centre that EMVI is being
detected at an appropriate rate and is of prognostic significance. This comprehensive study
assesses the reporting and prognostic significance of EMVI in a single centre, using pro-
spectively collected data from histopathology reports of a cohort of 2405 patients who
underwent surgery for colorectal cancer over a nine year period. Overall, EMVI was
reported in 27.9% of colorectal cancer excision specimens. In tumours (n = 1928) that had
not received neoadjuvant therapy, the presence of EMVI varied significantly depending on
tumour site (χ2 = 12.03, p<0.005), tumour stage (χ2 = 268.188, p<0.001), lymph node stage
(χ2 = 294.368, p<0.001) and Dukes’ stage (χ2 = 253.753, p<0.001). Multivariate analysis
confirmed EMVI as a significant independent prognostic indicator (p<0.001). In conclusion,
the presence of EMVI as an independent prognostic indicator is shown and is related to
other pathological and prognostic factors. This study emphasises the requirement for the
accurate identification of EMVI in colorectal cancer excision specimens and also under-
standing the relationship of EMVI with other prognostic factors.
Introduction
Colorectal carcinoma is the most common malignancy of the gastrointestinal tract and is a
leading cause of cancer related deaths [1]. Prognosis is predicted by the extent of tumour
spread locally, the presence of lymphatic system involvement and/or metastasis to other organs
which are encompassed in TNM or Dukes’ staging. Outwith these classical staging criteria, the
presence of tumour cells within veins outside the bowel wall (extramural venous invasion) is
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an important predictor of tumour recurrence or metastasis. Consequently extramural venous
invasion (EMVI) is an independent indicator of poor prognosis in colorectal carcinoma [2–
11]. It should be acknowledged that in addition to that of extramural venous channels, there is
an emerging role for intramural venous channels located in the submucosa or muscularis pro-
pria (intramural venous invasion, MVI) [5, 7]. However, the prognostic significance of MVI
alone is still unclear [4, 12].
Whilst not directly affecting overall tumour stage, the presence of EMVI does confer high
risk disease status [13, 14]. Indeed, about 25–30% of patients with lymph node negative disease
die from recurrent or metastatic disease, emphasising the role of vascular spread in colorectal
cancer dissemination [15–17].
Therefore, the United Kingdom Royal College of Pathologists (RCPath) has proposed a
minimum rate of detection of EMVI in colorectal cancer excision specimens. This study
reports on data collected from 2005 to 2013, during which time the RCPath dataset for colorec-
tal cancer (2nd edition) published in 2007 recommended a frequency of detection of EMVI of
20% [18].
EMVI was defined by Talbot and colleagues as the presence of tumour within an endothe-
lium-lined space that is either surrounded by a rim of muscle or contains red blood cells [19].
Additionally, the so called orphan artery sign is suggestive; where a rounded or elongated
tumour profile that is not in direct continuity with the advancing tumour margin is identified
adjacent to an artery, especially when no accompanying vein can be seen [3]. Whilst it is possi-
ble to detect EMVI on a haematoxylin and eosin stained slide, the application of ancillary tech-
niques such as elastin stains or immunohistochemistry have been shown to significantly
increase detection rates [2, 7, 8, 16, 20–24].
This comprehensive study assesses the trend in the evaluation of EMVI in a large cohort of
patients with colorectal cancer over a nine year period in a single centre, focusing on its prog-
nostic significance with respect to other colorectal cancer staging criteria and potential con-
founding factors.
Materials and Methods
Study population
This study included 2405 patients who had their colorectal cancer pathology resection speci-
mens reported by the Department of Pathology, Aberdeen Royal Infirmary from 2005–2013.
The Department of Pathology at Aberdeen Royal Infirmary is a regional pathology centre
receiving pathology specimens from four acute hospitals over three health authorities. Aber-
deen Royal Infirmary (an academic teaching hospital centre) and Dr Gray’s Hospital, Elgin (a
district general hospital) are both in NHS Grampian, while Balfour Hospital, Kirkwall (NHS
Orkney) and Gilbert Bain Hospital, Lerwick (NHS Shetland) are both remote and rural hospi-
tals. Approximately 75% of the colorectal cancer surgery is performed at Aberdeen Royal Infir-
mary. Relevant pathological data was extracted at the time of the weekly colorectal cancer
multidisciplinary team meeting from the pathology reports of the resected colorectal cancer
excision specimens and a database constructed.
The database was compiled using prospectively collected histopathological data from colo-
rectal cancers resected between 2005 and 2013. The information recorded in this database
includes age, gender, year of operation, administration of neoadjuvant therapy, whether the
tumour was screen detected, tumour site, tumour differentiation, tumour (T) stage, the pres-
ence of EMVI, total number of lymph nodes examined, number of lymph nodes involved by
metastatic tumour, lymph node (N) stage and Dukes’ stage. Information for each parameter
was available for every patient. Additionally, survival data (all-cause mortality) was available
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for a subset of 1004 patients (number of deaths = 243). The histopathology of all the cases in
this database were reported according to the criteria set out in the RCPath dataset for the
reporting of colorectal cancer excision specimens (2nd edition 2007–14) which incorporates
guidance from TNM5 and all cases were also subject to multi-disciplinary review [18].
Throughout this period of time NHS Grampian has been a centre for the NHS Scotland bowel
screening programme (2000–2006, pilot centre for evaluation of programme, 2007-part of
national programme following its implementation throughout Scotland).
Assessment of EMVI
The presence of tumour within venous structures beyond the bowel wall was assessed on hae-
matoxylin and eosin stained sections of tumour, with the additional use of elastic haematoxylin
and eosin staining in cases where EMVI was suspected but not clearly identified on micro-
scopic examination of the haematoxylin and eosin stained sections (Fig 1).
Statistics
The database was compiled in Excel 2007 and then imported into IBM SPSS version 21 for
Windows 7TM (IBM, Portsmouth, UK) to perform data analysis. Statistical comparisons
between groups were performed using chi-square (χ2) test. Survival curves were prepared using
the Kaplan-Meier method with log-rank (Mantel-Cox) analysis. Multivariate analysis with Cox
regression (proportional hazard analysis) was also performed.
Ethics
The project was carried out with ethics approval (ref. no. 08/S0801/81) from the North of Scot-
land research ethics committee. The research ethics committee did not require written partici-
pant consent and data was anonymised prior to analysis.
Results
The clinico-pathological parameters collected for the dataset are summarised in Table 1.
Fig 1. EMVI in colorectal cancer. (A) Haematoxylin and eosin. (B) Elastic haematoxylin and eosin.
doi:10.1371/journal.pone.0144987.g001
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In this study, EMVI was reported in 27.9% of all colorectal cancer cases (n = 2405). EMVI
was reported in 31.4% of cases where no neoadjuvant therapy had been received (n = 1928)
compared with 13.4% in cases receiving neoadjuvant therapy (n = 477). Cases were subse-
quently grouped for analysis into those that had received neoadjuvant therapy or those that
had not and cases that were screen detected or were not. Further subdivision into stage (pri-
mary tumour stage, lymph node stage or Dukes’ stage) and site of primary tumour was carried
out for analysis.
Table 1. Clinico-pathological characteristics of the patients and their tumours.
All cases
(n = 2405)
No neodjuvant
therapy (n = 1928)
Neoadjuvant therapy
(n = 477)
Non-screen
detected (n = 2077)
Bowel cancer screening
detected (n = 328)
Gender Male 54.7% (1315) 52.6% (1014) 63.1% (301) 53.6% (1113) 61.6% (202)
Female 45.2% (1088) 47.3% (912) 36.9% (176) 46.3 (962) 38.4% (126)
Unknown 0.1% (2) 0.1% (2) - 0.1% (2) -
Age <71 51.1% (1229) 47.8% (920) 64.8% (309) 47.4% (985) 74.4% (244)
71 48.8% (1173) 52% (1005) 35.2% (168) 52.5% (1089) 25.6% (84)
Unknown 0.1% (3) 0.2% (3) - 0.1% (3) -
Tumour site Proximal 41.5% (998) 51.2% (986) 2.5% (12) 42.5% (882) 35.4% (116)
Distal 31.1% (747) 37.9% (731) 3.4% (16) 30.0% (624) 37.5% (123)
Rectum 27.4% (660) 10.9% (211) 94.1% (449) 27.5% (571) 27.1% (89)
Tumour
differentiation
Well/
moderate
84.2% (2027) 86.6% (1669) 75.0% (358) 83.1% (1725) 90.9% (298)
Poor 11.6% (278) 13.4% (259) 4.0% (19) 12.6% (262) 4.9% (16)
n/a1 4.2% (100) - 21.0% (100) 4.1% (86) 4.3% (14)
Tumour stage T1 4.4% (106) 5.5% (106) - 3.6% (75) 9.5% (31)
T2 8.1% (194) 10.1% (194) - 7.1% (147) 14.3% (47)
T3 47.9% (1151) 59.7% (1151) - 47.8% (993) 48.2% (158)
T4 19.8% (477) 24.7% (477) - 21.5% (447) 9.2% (30)
yT0 4.5% (109) - 22.9% (109) 4.5% (94) 4.6% (15)
yT1 1.9% (46) - 9.6% (46) 1.9% (39) 2.1% (7)
yT2 4.2% (101) - 21.2% (101) 4.0% (84) 5.2% (17)
yT3 8.3% (199) - 41.7% (199) 8.5% (177) 6.7% (22)
yT4 0.9% (22) - 4.6% (22) 1% (21) 0.3% (1)
Lymph node
stage
N0 44.0% (1059) 54.9% (1059) - 43.0% (894) 50.3% (165)
N1 22.3% (537) 27.9% (537) - 22.6% (470) 20.4% (67)
N2 13.8% (332) 17.2% (332) - 14.4% (298) 10.4% (34)
yN0 15.0% (361) - 75.7% (361) 15.3% (317) 13.4% (44)
yN1 3.4% (82) - 17.2% (82) 3.2% (66) 4.88% (16)
yN2 1.4% (34) - 7.1% (34) 1.5% (32) 0.6% (2)
Dukes stage A 15.4% (370) 12.7% (244) 26.4% (126) 13.9% (288) 25% (82)
B 39.5% (949) 42.3% (815) 28.1% (134) 40.3% (857) 34.1% (112)
C 41.0% (985) 45.1% (869) 24.3% (116) 41.6% (865) 36.6% (120)
n/a1 4.2% (101) - 21.2% (101) 4.2% (87) 4.3% (14)
EMVI Yes 27.9% (670) 31.4% (606) 13.4% (64) 28.6% (593) 23.5% (77)
No 72.1% (1735) 68.6% (1322) 86.6 (413) 71.4% (1484) 76.52% (251)
1 n/a no residual tumour in the excision specimen and indicates a complete pathological response (i.e. ypT0N0) to neoadjuvant therapy
doi:10.1371/journal.pone.0144987.t001
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The relationship of EMVI with tumour site
Tumours were grouped into the categories of proximal (appendix, caecum, ascending colon,
hepatic flexure and transverse colon tumours), distal (splenic flexure, descending colon and
sigmoid colon tumours) and rectum depending on their anatomical location.
When all cases of colorectal cancer were considered (n = 2405), the frequency of EMVI dif-
fered significantly depending on the primary tumour site. EMVI was reported in 35.0% of
proximal, 29.0% of distal and 17.0% of rectum cases (χ2 = 66.83, p<0.001) (Fig 2).
In cases that had not received neoadjuvant therapy (n = 1928), the frequency of EMVI dif-
fered significantly depending on site of primary tumour. EMVI was reported in 35.0% of proxi-
mal, 28.0% of distal and 26.5% of rectum cases (χ2 = 12.03, p<0.005). For cases that had
received neoadjuvant therapy (n = 477), the frequency of EMVI differed significantly depend-
ing on site of primary tumour. EMVI was reported in 25.0% of proximal, 50.0% of distal and
11.8% of rectum cases (χ2 = 20.82, p<0.001).
When cases that had not been screen detected were analysed (n = 2077) the frequency of
EMVI differed significantly depending on site of primary tumour. EMVI was reported in
36.6% of proximal, 29.3% of distal and 15.2% of rectum cases (χ2 = 77.97, p<0.001). Whereas,
in screen detected cases (n = 328) EMVI reporting did not differ significantly between sites of
primary tumour. EMVI was reported in 21.6% of proximal, 24.4% of distal and 24.7% of rec-
tum cases (χ2 = 0.373, p = 0.830).
The relationship of EMVI with tumour stage
The rate of EMVI also varied significantly depending on tumour (T) stage of primary tumour
when all cases were considered. EMVI was reported in 1.8% of T0 (complete pathological
response of primary tumour to neoadjuvant therapy), 0.7% of T1, 3.4% of T2, 27.6% of T3 and
56.9% of T4 tumours (χ2 = 390.212, p<0.001) (Fig 3).
In cases that had not received neoadjuvant therapy, EMVI was present in 0.9% of T1
tumours, 3.6% of T2 tumours, 28.2% of T3 tumours and 57.2% T4 tumours (χ2 = 268.188,
p<0.001). For cases that had received neoadjuvant therapy, the presence of EMVI differed sig-
nificantly depending on T stage of primary tumour. EMVI was reported in 1.8% of T0, 0% of
T1, 3.0% of T2, 24.1% of T3 and 50% of T4 cases (χ2 = 74.173, p<0.001).
When cases that had not been screen detected were analysed, the presence of EMVI differed
significantly depending on T stage of primary tumour. EMVI was reported in 2.1% of T0, 0%
of T1, 2.6% of T2, 27.1% of T3 and 57.3% of T4 cases (χ2 = 344.376, p<0.001). There was also a
significant difference in the frequency of EMVI depending on T stage of primary tumour in
screen detected cases. EMVI was reported in 0% of T0, 2.6% of T1, 6.2% of T2, 31.1% of T3
and 51.6% of T4 cases (χ2 = 43.866, p<0.001).
The relationship of EMVI with lymph node stage
When all cases were considered, the presence of EMVI differed significantly depending on
lymph node (N) stage of primary tumour. EMVI was reported in 14.9% of N0, 35.5% of N1
and 65.3% of N2, cases (χ2 = 392.878, p<0.001) (Fig 4).
In cases that had not received neoadjuvant therapy, there was a significant difference in
EMVI rate depending on N stage, with EMVI present in 17.5% of N0, 37.2% of N1 and 66.6%
of N2 tumours respectively (χ2 = 294.368, p<0.001). When cases that had received neoadju-
vant therapy are considered, there is also a significant difference in EMVI rate depending on
N stage. EMVI was present in 7.2% of N0, 24.4% of N1 and 52.9% of N2 tumours respectively
(χ2 = 66.222, p<0.001).
EMVI and Colorectal Cancer
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Cases that were not screen detected showed a significant difference in EMVI rate depending
on N stage, with EMVI present in 15.1% of N0, 35.6% of N1 and 66.4% of N2 tumours respec-
tively (χ2 = 351.707, p<0.001). A significant difference in the frequency of EMVI depending
Fig 2. Frequency of EMVI in relation to site of primary tumour. (A) All cases. (B) Cases that had not received neoadjuvant therapy. (C) Cases that had
received neoadjuvant therapy. (D) Non-screen-detected cases. (E) Bowel cancer screening detected cases.
doi:10.1371/journal.pone.0144987.g002
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on N stage was also seen in cases that had been screen detected, with EMVI present in 13.4% of
N0, 34.9% of N1 and 55.6% of N2 cases respectively (χ2 = 38.513, p<0.001).
The relationship of EMVI with Dukes’ stage
The frequency of EMVI reporting in different Dukes’ stage tumours was also considered.
When all cases were analysed, EMVI was reported in 1.1% of Dukes’ A cases, 21.6% of Dukes’
B cases and 46.8% of Dukes’ C cases. (χ2 = 365.373, p<0.001) (Fig 5).
For cases that had not received neoadjuvant therapy EMVI was reported in 1.2% of Dukes’
A cases, 22.2% of Dukes’ B cases and 48.6% of Dukes’ C cases (χ2 = 253.753, p<0.001). In cases
that had received neoadjuvant therapy, EMVI was reported in 0.8% of Dukes’ A cases, 17.9% of
Dukes’ B cases and 33.6% of Dukes’ C cases (χ2 = 76.022, p<0.001).
In non-screen detected cases, EMVI was reported in 0.3% of Dukes’ A cases, 21.6% of
Dukes’ B cases and 47.5% of Dukes’ C cases (χ2 = 319.239, p<0.001). For those cases that were
screen detected, EMVI was reported in 3.7% of Dukes’ A, 21.4% of Dukes’ B and 41.7% of
Dukes’ C tumours (χ2 = 44.586, p<0.001).
EMVI and survival analysis
Follow-up data were available for all-cause mortality over an 86 month period in 1004 of the
2405 patients in the database (41.7%). Of these, 190 (18.9%) cases had EMVI and 814 (81.1%)
did not. When all cases were considered, EMVI reduced patient survival over time and these
survival distributions were statistically different (χ2 = 117.110, p<0.001, HR = 0.207 (95% CI
0.159–0.269), Mantel-Cox log-rank test) (Fig 6).
Survival data was available for 731 of the cases that had not received neoadjuvant therapy.
Of these, 166 (22.7%) had EMVI and 565 (77.3%) did not. The presence of EMVI was associ-
ated with significantly reduced patient survival over time (χ2 = 113.741, p<0.001, HR = 0.241
(95% CI 0.182–0.321, Mantel-Cox log-rank test).
Survival data was available for 273 of the cases that had received neoadjuvant therapy. Of
these, 24 (8.8%) had EMVI and 249 (91.2%) did not. The presence of EMVI was associated
with significantly reduced patient survival over time (χ2 = 43.639, p<0.001, HR = 0.140 (95%
CI 0.071–0.277, Mantel-Cox log-rank test).
When the cases of colon cancer that had not received neoadjuvant therapy (n = 653) were
considered, 154 (23.6%) had EMVI and 499 (76.4%) did not. The presence of EMVI was associ-
ated with significantly reduced patient survival over time (χ2 = 99.888, p<0.001, HR = 0.247
(95% CI 0.184–0.333, Mantel-Cox log-rank test).
When all rectal cancers (n = 306) were considered, EMVI was present in 34 (11.1%) and
absent in 359 (89.9%) of cases. The presence of EMVI was associated with significantly reduced
patient survival over time (χ2 = 61.300, p<0.001, HR = 0.138 (95% CI 0.077–0.246, Mantel-
Cox log-rank test). Selection of rectal cancer cases that had received neoadjuvant therapy
(n = 262) showed that 22 cases (8.4%) had EMVI and 240 cases (91.6%) did not. The presence
of EMVI was associated with significantly reduced patient survival over time (χ2 = 42.397,
p<0.001, HR = 0.133 (95% CI 0.065–0.272, Mantel-Cox log-rank test). A total of 78 rectal can-
cers had not received neoadjuvant therapy. Of these, 12 (15.4%) had EMVI and 66 (84.6%) did
not. The presence of EMVI was associated with significantly reduced patient survival over time
(χ2 = 16.914, p = 0.001, HR = 0.154 (95% CI 0.056–0.425, Mantel-Cox log-rank test).
Fig 3. Frequency of EMVI reporting per tumour (T) stage of primary tumour. (A) All cases. (B) Cases that had not received neoadjuvant therapy. (C)
Cases that had received neoadjuvant therapy. (D) Non-screen-detected cases. (E) Bowel cancer screening detected cases. T0 represents cases in which
there was a complete pathological response of the primary tumour to neoadjuvant therapy.
doi:10.1371/journal.pone.0144987.g003
EMVI and Colorectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0144987 December 15, 2015 8 / 20
Fig 4. Frequency of EMVI reporting per lymph node (N) stage of primary tumour. (A) All cases. (B) Cases that had not received neoadjuvant therapy.
(C) Cases that had received neoadjuvant therapy. (D) Non-screen-detected cases. (E) Bowel cancer screening detected cases.
doi:10.1371/journal.pone.0144987.g004
EMVI and Colorectal Cancer
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When all cases of Dukes’ B colorectal cancers were analysed (n = 372), EMVI was present in
56 (15.1%) and not present in 316 (84.9%). The presence of EMVI was associated with signifi-
cantly reduced patient survival over time (χ2 = 22.607, p<0.001, HR = 0.289 (95% CI 0.167–
0.499, Mantel-Cox log-rank test) (Fig 7).
For Dukes’ B cases that had not received neoadjuvant therapy (n = 301), 51 (16.9%) had
EMVI and 250 (83.1%) did not. The presence of EMVI was associated with significantly
reduced patient survival over time (χ2 = 21.370, p<0.001, HR = 0.272 (95% CI 0.151–0.492,
Mantel-Cox log-rank test).
Survival data was available for 71 Dukes’ B colorectal cancer cases that had received neoad-
juvant therapy. A total of 5 (7.0%) had EMVI and 66 (93%) did not. The presence of EMVI was
not associated with significantly reduced patient survival over time (χ2 = 0.874, p = 0.350,
HR = 0.492 (95% CI 0.107–2.264, Mantel-Cox log-rank test).
When all cases of Dukes’ C colorectal cancers were analysed (n = 390), EMVI was present in
132 (33.0%) and not present in 267 (67.0%). The presence of EMVI was associated with signifi-
cantly reduced patient survival over time (χ2 = 68.688, p<0.001, HR = 0.279 (95% CI 0.202–
0.386, Mantel-Cox log-rank test) (Fig 8).
For Dukes’ C cases that had not received neoadjuvant therapy (n = 319), 113 (35.4%) had
EMVI and 206 (64.6%) did not. The presence of EMVI was associated with significantly
reduced patient survival over time (χ2 = 54.319, p<0.001, HR = 0.291 (95% CI 0.205–0.414,
Mantel-Cox log-rank test).
Survival data was available in 71 Dukes’ C colorectal cancer cases that had received neoadju-
vant therapy. A total of 19 (26.8%) had EMVI and 52 (73.2%) did not. The presence of EMVI
was associated with significantly reduced patient survival over time (χ2 = 12.286, p<0.001,
HR = 0.246 (95% CI 0.105–0.577, Mantel-Cox log-rank test).
There were 879 colorectal cancer cases in the non-screen-detected group for which survival
data was available. Of these, 167 (19.0%) had EMVI and 712 (81.0%) did not. The presence of
EMVI was associated with significantly reduced patient survival over time (χ2 = 178.264,
p<0.001, HR = 0.191 (95% CI 0.146–0.251, Mantel-Cox log-rank test). There were 638 non-
screen-detected colorectal cancers that had not received neoadjuvant therapy. Of these, 147
(23.0%) had EMVI and 491 (77%) did not. The presence of EMVI was associated with signifi-
cantly reduced patient survival over time (χ2 = 117.721, p<0.001, HR = 0.226 (95% CI 0.168–
0.303, Mantel-Cox log-rank test). A total of 241 non-screen-detected colorectal cancer cases
that had received neoadjuvant therapy were available for survival analysis. Twenty cases (8.3%)
had EMVI and 221 cases (91.7%) did not. The presence of EMVI was associated with signifi-
cantly reduced patient survival over time (χ2 = 50.759, p<0.001, HR = 0.115 (95% CI 0.056–
0.235, Mantel-Cox log-rank test) (Fig 9).
Of the bowel cancer screening detected cases in which survival data was available (n = 125),
23 (18.4%) had EMVI and 102 (81.6%) did not. In this group, EMVI was not associated with a
significantly reduced patient survival over time (χ2 = 3.237, p = 0.072, HR = 0.384 (95% CI
0.130–1.133, Mantel-Cox log-rank test). Within this group, 93 had not received neoadjuvant
therapy. 19 (20.4%) had EMVI and 74 (79.6%) did not. There was no significant reduction in
patient survival over time in this group (χ2 = 1.498, p = 0.221, HR = 0.486 (95% CI 0.149–
1.584, Mantel-Cox log-rank test).
Fig 5. Frequency of EMVI reporting per Dukes’ stage of primary tumour. (A) All cases. (B) Cases that had not received neoadjuvant therapy. (C) Cases
that had received neoadjuvant therapy. (D) Non-screen-detected cases. (E) Bowel cancer screening detected cases.
doi:10.1371/journal.pone.0144987.g005
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Multivariate analysis
Multi-variate analysis showed that EMVI was a highly significant independent prognostic fac-
tor (p<0.001) when other tumour dependent factors including tumour stage, lymph node
stage, Dukes stage, tumour site and degree of tumour differentiation as well as patient specific
factors of age and gender are considered (Tables 2 and 3).
Fig 6. Relationship between extramural venous invasion and survival. (A) All patients (n = 1004). (B)
Patients who did not receive neoadjuvant therapy (n = 731). (C) Patients who received neoadjuvant therapy
(n = 273). (D) Colon cancer cases that did not receive neoadjuvant therapy (n = 653). (E) All rectal cancer
cases (n = 396). (F) Rectal cancer cases that received neoadjuvant therapy (n = 318). (G) Rectal cancer
cases that did not receive neoadjuvant therapy (n = 78).
doi:10.1371/journal.pone.0144987.g006
Fig 7. Relationship between extramural venous invasion and survival in Dukes’ B cancers. (A) All patients (n = 372). (B) Patients who did not receive
neoadjuvant therapy (n = 301). (C) Patients who received neoadjuvant therapy (n = 71).
doi:10.1371/journal.pone.0144987.g007
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EMVI was not a significant prognostic cofactor in screen detected cases but was in non-
screen detected cases (Tables 4 and 5).
Discussion
It is important for individual centres reporting colorectal excision specimen to demonstrate an
appropriate frequency of detection of pathological prognostic factors taking account of con-
founding factors e.g. proportion of patients receiving neoadjuvant therapy and proportion of
cases identified through a bowel cancer screening programme. Individual centres should also
demonstrate that the pathological factors that are assumed to be prognostically significant are
indeed prognostically significant in their population. This large study from a single centre
Fig 8. Relationship between extramural venous invasion and survival in Dukes’ C cancers. (A) All patients (n = 390). (B) Patients who did not receive
neoadjuvant therapy (n = 319). (C) Patients who received neoadjuvant therapy (n = 71).
doi:10.1371/journal.pone.0144987.g008
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Fig 9. Relationship between extramural venous invasion and survival and screening in colorectal cancers. (A) All non-screen detected cancer
patients (n = 879). (B) Non-screen-detected cancer patients who did not receive neoadjuvant therapy (n = 638). (C) Non-screen-detected cancer patients
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utilises prospectively collected data to comprehensively assess the evaluation of EMVI in colo-
rectal cancer resection specimens over a nine year period and to consider potential confound-
ing factors including neoadjuvant therapy and the influence of bowel cancer screening. It uses
a prospectively collected dataset to examine in detail the significance of the reporting of EMVI
on mortality in this population. All of the data derives from a single histopathology depart-
ment, thereby reducing data collection and reporting bias.
There is well documented variation between centres in the demonstration of EMVI [1, 5, 7,
12, 16, 19–27]. Despite which, EMVI is recognised as an important prognostic feature [12, 16,
22, 28–30]. As such, reporting of the presence or absence of EMVI in colorectal cancer excision
specimens is recommended by professional organisations including the Royal College of
Pathologists (UK) and the College of American Pathologists [3, 9]. The consequence of accu-
rate detection of EMVI is that patients with lymph node negative colorectal cancer (stage II/
Dukes’ B disease) but with EMVI and/or other adverse prognostic features (including tumour
perforation, serosal involvement, incomplete tumour resection) may benefit from and should
be considered for adjuvant chemotherapy [14, 31, 32]. The presence of EMVI has become
prognostically more relevant following the introduction in the UK of bowel cancer screening
programmes, as this has resulted in the more frequent resection of lymph node negative
tumours.
This study shows that when all cases are analysed, detection of EMVI exceeds the standard
set by the Royal College of Pathologists over the same time period [18]. In addition, exclusion
of cases in which preoperative neoadjuvant therapy had been given and which were potentially
down staged, resulted in both the 2nd edition RCPath standard (20%) as well as the revised 3rd
edition (2014) RCPath standard (30%) being surpassed [3, 18]. Albeit the data included in this
study is prior to the publication of the third edition of the RCPath colorectal cancer dataset [3].
who received neoadjuvant therapy (n = 241). (D) All bowel cancer screening detected cases (n = 125). (E) Bowel cancer screening detected patients who did
not receive neoadjuvant therapy (n = 93).
doi:10.1371/journal.pone.0144987.g009
Table 2. The relationship between clinico-pathological characteristics and overall survival, when tumour stage and lymph node status are covari-
ates and primary tumour site is grouped as proximal, distal or rectum.
All cases Cases that had not received
neoadjuvant therapy
Cases that had received neoadjuvant
therapy
Wald
value
p-
value
Hazard
ration
95% CI Wald
value
p-
value
Hazard
ratio
95% CI Wald
value
p-
value
Hazard
ratio
95% CI
EMVI (present,
absent)
47.415 <0.001 0.357 0.266–
0.478
39.174 <0.001 0.364 0.265–
0.499
11.154 0.001 0.256 0.115–
0.570
Age (<71, 71) 46.731 <0.001 2.595 1.974–
3.410
36.725 <0.001 2.572 1.895–
3.492
9.739 0.002 2.837 1.474–
5.462
Tumour stage (pT0,
pT1, pT2, pT3, pT4)
46.006 <0.001 0.384 0.000–
0.528
39.757 <0.001 0.390 0.156–
0890
3.079 0.545 0.335 0.000–
1.399
Lymph node stage
(pN0, pN1, pN2)
30.536 <0.001 0.693 0.258–
0.977
24.985 <0.001 0.648 0.252–
0.937
5.369 0.068 1.821 0.234–
5.241
Tumour site (proximal,
distal, rectum)
2.669 0.263 0.843 0.500–
1.201
3.823 0.148 0.729 0.356–
1.213
1.896 0.387 3.147 0.260–
16.32
Tumour differentiation
(well/moderate, poor)
1.100 0.577 0.827 0.000–
1.180
0.004 0.953 0.988 0.672–
1.453
9.583 0.008 0.178 0.000–
0.531
Gender (M, F) 0.000 0.985 1.002 0.775–
1.926
0.272 0.602 1.078 0.813–
1.428
0.087 0.768 0.900 0.445–
1.820
doi:10.1371/journal.pone.0144987.t002
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As might be expected, EMVI is more common in higher stage (T-, N- and Dukes’ stage)
tumours and this study has demonstrated a stage dependent significant difference irrespective
of whether the cases were screen-detected or not or if there had been neoadjuvant therapy or
not. It has also shown the frequency of the identification of EMVI varied significantly depend-
ing on site of primary tumour when all cases, non-screen-detected cases, cases that had
received neoadjuvant therapy and also those cases that had not. There was no significant
tumour site dependent difference in the frequency of EMVI reporting in colorectal cancer
cases that were detected by the bowel screening programme. It is not clear if that represent the
smaller number of bowel cancer screening detected cases or reflects a difference in the biology
between symptomatic colorectal cancer and screen detected cancers.
Table 3. The relationship between clinico-pathological characteristics and overall survival, when Dukes’ stage is a covariate and primary tumour
site is grouped as proximal, distal or rectum.
All cases Cases that had not received
neoadjuvant therapy
Cases that had received neoadjuvant
therapy
Wald
value
p-
value
Hazard
ratio
95% CI Wald
value
p-
value
Hazard
ratio
95% CI Wald
value
p-
value
Hazard
ratio
95% CI
EMVI (present,
absent)
73.655 <0.001 0.293 0.222–
0.388
62.550 <0.001 0.296 0.219–
0.400
12.239 <0.001 0.252 0.116–
0.545
Age (<71, 71) 47.278 <0.001 2.603 1.982–
3.418
36.090 <0.001 2.526 1.867–
3.417
10.447 0.001 2.976 1.538–
5.759
Dukes’ stage (A, B,
C)
37.981 <0.001 9.910 0.318–
105.506
27.331 <0.001 0.776 0.519–
1.062
8.594 0.035 17.280 0.230–
320.371
Tumour site
(proximal, distal,
rectum)
3.612 0.057 1.023 0.629–
1.447
2.092 0.351 0.990 0.667–
1.236
5.111 0.078 4.978 0.498–
23.083
Tumour
differentiation (well/
moderate, poor)
3.054 0.217 0.788 0.110–
5.673
0.565 0.452 0.866 0.596–
1.260
10.678 0.005 0.280 0.031–
2.567
Gender (M, F) 0.000 0.985 1.002 0.776–
1.296
0.278 0.598 1.079 0.814–
1.429
0.078 0.780 0.905 0.447–
1.829
doi:10.1371/journal.pone.0144987.t003
Table 4. The relationship between clinico-pathological characteristics and overall survival when tumour and lymph node stage are covariates and
primary tumour site is grouped as proximal, distal or rectum.
Non-screen detected cases Bowel cancer screening detected cases
Wald
value
p-
value
Hazard
ratio
95% CI Wald
value
p-
value
Hazard
ratio
95% CI
EMVI (present, absent) 50.752 <0.001 0.327 0.241–
0.445
0.177 0.674 0.723 0.160–3.268
Tumour stage (pT0, pT1, pT2, pT3, pT4) 42.463 <0.001 0.383 0.000–
0.571
2.303 0.680 0.325 0.000–4.351
Age (<71, 71) 41.215 <0.001 2.527 1.904–
3.354
0.459 0.498 1.646 0.390–6.949
Lymph node stage (pN0, pN1, pN2) 27.403 <0.001 0.696 0.256–
0.997
3.971 0.137 0.671 0.231–2.899
Tumour site (proximal, distal, rectum) 4.231 0.121 0.741 0.450–
1.072
2.201 0.333 3.319 0.231–
19.977
Tumour differentiation (well/moderate,
poor)
1.378 0.502 0.802 0.000–
1.160
0.465 0.792 0.520 0.000–3.403
Gender (M, F) 0.062 0.803 0.967 0.741–
1.262
0.721 0.396 1.640 0.523–5.137
doi:10.1371/journal.pone.0144987.t004
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Whilst the frequency of EMVI appears closely related to tumour stage, multivariate analysis
has shown that EMVI is an independent predictor of poor prognosis, as are patient age and
tumour stage. This study allowed assessment of all-cause mortality in a subgroup of patients.
Overall, EMVI was associated with statistically significantly reduced survival. Only in screen-
detected cases (n = 125) and in Dukes’ B cases following neoadjuvant therapy (n = 71) was
EMVI not associated with a significant reduction in survival. However, this lack of significance
may reflect the limited amount of survival data available in those groups.
EMVI is clearly an important parameter with regards to patient prognosis and the post-
operative management of colorectal cancer. Adequate reporting is therefore paramount and
may be optimised with the use of ancillary techniques such as elastic haematoxylin and eosin
staining [2, 7, 8, 16, 20–23]. The data presented supports the need for accurate assessment and
reporting of EMVI along with other prognostic factors such as lymph node yield, lymph node
ratio and relevant biomarkers to facilitate the decision making process of colorectal cancer
treatment [33–37].
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